Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...
Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.
Analysts have been eager to weigh in on the Healthcare sector with new ratings on 4D Molecular Therapeutics (FDMT – Research Report) and ...
Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.
Israel carried out one of the most intense bombardments of the past year, as warplanes launched 70 airstrikes, Lebanese security officials said. The barrage came shortly after Hezbollah’s leader ...
EY Pune employee's death: Shobha Karandlaje was responding to Rajeev Chandrasekhar's post who called the woman's death very sad and “disturbing at many levels”.
Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...
Out of 50 states, just seven are likely to decide whether Donald Trump or Kamala Harris will win the 2024 US elections. With election day on the horizon, each candidate is looking to turn as many ...